Alimera Sciences (ALIM) – Company Press Releases
-
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
-
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
-
Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update
-
The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access
-
Alimera Completes Recruitment for the Synchronicity Study
-
Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Alimera Appoints Maggie A. Pax to Its Board of Directors
-
Alimera Announces Scientific Data Highlighting ILUVIEN® To Be Presented at the American Academy of Ophthalmology
-
Alimera Sciences Reports Third Quarter 2023 Results
-
Alimera Sciences to Report Third Quarter 2023 Financial Results on October 26, 2023, and Provide Corporate Update
-
Alimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Annual Congress
-
Alimera Sciences Appoints Jason Werner as Chief Operating Officer
-
Alimera Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
-
Alimera Sciences Reports Second Quarter 2023 Results
-
Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline
-
Alimera Sciences to Report Second Quarter 2023 Financial Results on August 10, 2023, and Provide Corporate Update
-
Alimera Completes Recruitment for its Landmark NEW DAY Study
-
Alimera Acquires U.S. Commercial Rights to YUTIQ®
-
Alimera Sciences to Host Rescheduled Corporate Update Call on Thursday, May 18, 2023, at 8:30am ET
-
Alimera Sciences Reports First Quarter 2023 Results
-
Alimera Sciences to Report First Quarter 2023 Financial Results on May 15, 2023, and Provide Corporate Update
-
Alimera Data to be Featured in Scientific Programming at Upcoming Annual Congress
-
Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in the Nordic Countries
-
Alimera Sciences Announces 2022 Financial Results and Business Update
-
Alimera Improves Capital Structure, Strengthens Balance Sheet and Extends Term Loan Facility
-
Alimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 31, 2023, and Provide Corporate Update
-
Alimera Appoints Roger Sawhney, M.D. to Its Board of Directors
-
Alimera Announces Submission of Marketing Authorization Application in Switzerland for ILUVIEN®
-
Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officer
-
Alimera Sciences Announces Agreement to Extend Amortization Date and Interest-Only Period on Loan Agreement
-
Alimera Highlights Abstracts Regarding Consensus Among US Retina Specialists and Reduced Retinal Thickness Variability Leading to Improved Visual Outcomes Following ILUVIEN® Administration
-
Alimera Sciences Announces Third Quarter 2022 Financial Results
-
Alimera Sciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022, and Provide Corporate Update
-
Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in the Czech Republic
-
Paladin Phase 4 Study Confirms ILUVIEN® Patients' Reduced Need for Multiple Treatments
-
Alimera Announces Agreement with Jaeb Center for Health Research on Behalf of the DRCR Retina Network
-
Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Ireland
-
Alimera Announces Multiple Abstracts Highlighting ILUVIEN® Real World Data at EURETINA Annual Congress
-
Alimera Sciences to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
-
Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Portugal
-
Alimera Sciences Announces Second Quarter 2022 Financial Results
-
Paladin Phase 4 Study Confirms Safety of Durable ILUVIEN® Treatment and Reduces Burden of Care For DME Patients
-
Alimera Sciences to Report Second Quarter 2022 Financial Results on Wednesday, July 27, 2022, and Provide Corporate Update
-
Alimera Announces Pricing and Reimbursement of Uveitis Indication Granted for ILUVIEN® in France
-
Alimera Announces Data to Be Highlighted In Scientific Programming At Annual Congress
-
Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy
-
Phase III Clinical Study IND Accepted in China for Alimera’s Fluocinolone Acetonide Intravitreal Implant
-
Alimera Sciences to Present at the LD Micro Invitational XII Conference
Back to ALIM Stock Lookup
